CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2014—TriLink BioTechnologies has signed a licensing agreement with Biofortuna for use of its CleanAmp dNTPs in Biofortuna’s freeze-drying (lyophilized) contract development and production service.
In 2010, Biofortuna licensed TriLink’s CleanAmp dNTPs for use in its molecular diagnostic kits, SSPGo, which are distributed exclusively by Abbott Molecular for the HLA, transplantation, disease identification, and PGx market. The expanded CleanAmp license gives Biofortuna the right to incorporate CleanAmp dNPTs into its recently launched freeze-drying molecular diagnostic kit development and production service.
When developing SSPGo (complete freeze-dried PCR reaction kits stabilized at ambient temperatures for up to 16 months), CleanAmp dNTPs gave Biofortuna a viable hot start PCR alternative that improved specificity by simple replacement of standard dNTPs with CleanAmp dNTPs. Now the advantages of these combined technologies are available to all diagnostic kit developers.
TriLink BioTechnologies, 858-546-0004